Nautilus Biotechnology (NAUT) 10-Q 30 Apr 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	Apr. 25, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-39434
Entity Registrant Name	NAUTILUS BIOTECHNOLOGY, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	98-1541723
Entity Address, Address Line One	2701 Eastlake Avenue East
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98102
City Area Code	206
Local Phone Number	333-2001
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NAUT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		125,265,015
Entity Central Index Key	0001808805
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 25,729	$ 19,397
Short-term investments	155,637	154,021
Prepaid expenses and other current assets	3,728	3,419
Total current assets	185,094	176,837
Property and equipment, net	4,525	4,267
Operating lease right-of-use assets	31,559	32,634
Long-term investments	66,292	90,647
Other long-term assets	1,180	1,180
Total assets	288,650	305,565
Current liabilities:
Accounts payable	1,860	1,639
Accrued expenses and other liabilities	3,677	3,945
Current portion of operating lease liabilities	3,675	3,538
Total current liabilities	9,212	9,122
Operating lease liabilities, net of current portion	29,946	31,090
Total liabilities	39,158	40,212
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.0001 par value, 200,000,000 authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 125,265,015 and 125,068,601 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	13	13
Additional paid-in capital	471,193	467,834
Accumulated other comprehensive income (loss)	(745)	(255)
Accumulated deficit	(220,969)	(202,239)
Total stockholders’ equity	249,492	265,353
Total liabilities and stockholders' equity	$ 288,650	$ 305,565

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	200,000,000	200,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	125,265,015	125,068,601
Common stock, shares outstanding (in shares)	125,265,015	125,068,601

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 12,930	$ 10,877
General and administrative	8,677	7,183
Total operating expenses	21,607	18,060
Other income (expense)
Interest income	2,877	3,098
Other expense	0	(3)
Total other income	2,877	3,095
Net loss	$ (18,730)	$ (14,965)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.15)	$ (0.12)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.15)	$ (0.12)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	125,135,451	124,590,351
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	125,135,451	124,590,351

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (18,730)	$ (14,965)
Other comprehensive income (loss):
Unrealized gain (loss) on securities available-for-sale	(490)	895
Total other comprehensive income (loss)	(490)	895
Comprehensive loss	$ (19,220)	$ (14,070)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022		124,865,485
Beginning balance at Dec. 31, 2022	$ 314,924	$ 12	$ 455,330	$ (1,854)	$ (138,564)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of vested stock options (in shares)		907
Issuance of common stock upon exercise of vested stock options	1		1
Stock-based compensation expense	2,860		2,860
Other comprehensive income (loss)	895			895
Net loss	(14,965)				(14,965)
Ending balance (in shares) at Mar. 31, 2023		124,866,392
Ending balance at Mar. 31, 2023	303,715	$ 12	458,191	(959)	(153,529)
Beginning balance (in shares) at Dec. 31, 2023		125,068,601
Beginning balance at Dec. 31, 2023	$ 265,353	$ 13	467,834	(255)	(202,239)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of vested stock options (in shares)	196,414	196,414
Issuance of common stock upon exercise of vested stock options	$ 245		245
Stock-based compensation expense	3,114		3,114
Other comprehensive income (loss)	(490)			(490)
Net loss	(18,730)				(18,730)
Ending balance (in shares) at Mar. 31, 2024		125,265,015
Ending balance at Mar. 31, 2024	$ 249,492	$ 13	$ 471,193	$ (745)	$ (220,969)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (18,730)	$ (14,965)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	3,114	2,860
Amortization of operating lease right-of-use assets	1,075	786
Depreciation	516	385
Amortization (accretion) of premium (discount) on securities, net	(751)	(669)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(309)	(513)
Accounts payable	94	53
Accrued expenses and other liabilities	(268)	65
Operating lease liabilities	(1,007)	(526)
Net cash used in operating activities	(16,266)	(12,524)
Cash flows from investing activities
Proceeds from maturities of securities	23,000	14,249
Purchases of securities	0	(27,052)
Purchases of property and equipment	(647)	(692)
Net cash provided by (used in) investing activities	22,353	(13,495)
Cash flows from financing activities
Proceeds from exercise of stock options	245	1
Net cash provided by financing activities	245	1
Net increase (decrease) in cash, cash equivalents and restricted cash	6,332	(26,018)
Cash, cash equivalents and restricted cash at beginning of period	20,399	115,477
Cash, cash equivalents and restricted cash at end of period	26,731	89,459
Supplementary cash flow information on non-cash activities:
Acquisitions of property and equipment included in accounts payable	275	115
Right-of-use asset obtained in exchange for operating lease liability	$ 0	$ 7,623

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Nautilus Biotechnology, Inc. (the “Company”) is a biotechnology company incorporated in 2016 with corporate headquarters in Seattle, Washington and research and development headquarters in San Carlos, California. Since the Company’s incorporation in 2016, the Company has devoted substantially all of its resources to research and development activities, including with respect to its proteomics platform, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital and providing general and administrative support for these operations. On June 9, 2021, Nautilus Biotechnology, Inc. a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp. III, a Cayman Islands exempted company and the Company’s predecessor company (“ARYA”)), consummated the business combination (the “Business Combination”) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the “BCA”), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (“Mako Merger Sub”), and Nautilus Subsidiary, Inc., a Delaware corporation (f/k/a Nautilus Biotechnology, Inc.) (“Legacy Nautilus”). As a result of the Business Combination, ARYA changed its name to “Nautilus Biotechnology, Inc.” and Mako Merger Sub merged with and into Legacy Nautilus with Legacy Nautilus surviving as the surviving company and becoming a wholly-owned subsidiary of ARYA (the “Merger” and, collectively with the other transactions described in the BCA, the “Reverse Recapitalization”). In addition, in conjunction with the completion of the Business Combination, certain investors (“PIPE Investors”) subscribed for the purchase of an aggregate of 20,000,000 shares of common stock of the Company (“New Nautilus Common Stock”) at a price of $10.00 per share for aggregate gross proceeds of $200.0 million (“PIPE Financing”). Basis of Presentation The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for interim financial reporting. All intercompany transactions and balances have been eliminated upon consolidation. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements were prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods. The interim financial results are not necessarily indicative of the results for a full year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 on file with the SEC. The Company’s reporting currency is the U.S. dollar. Going Concern The Company’s condensed consolidated financial statements have been prepared on the basis of continuity of operations, the realization of assets, and the satisfaction of liabilities in the ordinary course of business. Since inception, the Company has been engaged in developing its technology, raising capital, and recruiting personnel. The Company’s operating plan may change as a result of many factors currently unknown and there can be no assurance that the current operating plan will be achieved in the time frame anticipated by the Company, and it may need to seek additional funds sooner than planned. If adequate funds are not available to the Company on a timely basis, it may be required to delay, limit, reduce, or terminate certain commercial efforts, or pursue merger or acquisition strategies, all of which could adversely affect the holdings or the rights of the Company’s stockholders. The Company has incurred net operating losses and negative cash flows from operations in every year since inception and expects this to continue for the foreseeable future. As of March 31, 2024, the Company had an accumulated deficit of $221.0 million.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determining the estimated lives of property and equipment, stock-based compensation, research and development accruals, and the valuation allowance for deferred tax assets. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods. As future events and their effects cannot be determined with precision, actual results could materially differ from those estimates and assumptions. Concentrations of Credit Risk and Other Risks and Uncertainties Credit risk represents the accounting loss that would be recognized as of the reporting date if counterparties failed to perform as contracted. Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash balances maintained in excess of federal depository insurance limits and investments in marketable debt securities that are not federally insured. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk on cash or investments. The Company relies, and expects to continue to rely, on a number of vendors to provide services, supplies and materials related to its research and development programs. The Company relies on single source suppliers for certain components and materials used in the Nautilus platform. The loss of any of these single source suppliers would require the Company to expend significant time and effort to locate and qualify an alternative source of supply for these components. The Company also relies, and expects to continue to rely, on third-party manufacturers and, in many cases, single third-party manufacturers for the production of certain reagents and antibodies. These programs could be adversely affected by a significant interruption in these services or the availability of materials. The Company is subject to risks similar to those of pre-clinical stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of negative global and national events and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products. Segment Reporting Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision m aker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s Chief Executive Officer is its CODM. The Company’s CODM re views financial information presented on a consolidated basis for the purposes of making operating decisions, allocating resources and evaluating financial performance. As such, the Company has determined that it operates in one operating and one reportable segment. The Company’s long-lived assets are entirely based in the United States. Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less as of the date of acquisition to be cash equivalents. Investments The Company considers investments with an original maturity greater than three months and remaining maturities less than one year to be short-term investments. The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as long-term investments. The Company classifies its marketable debt securities as available for sale and reports them at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For investments sold prior to maturity, the cost of investments sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in other income (expense), net in the condensed consolidated statement of operations. If the estimated fair value of a marketable debt security is below its amortized cost basis, the Company evaluates whether it is more likely than not that the Company will be required to sell the security before its anticipated recovery in market value and whether credit losses exist for the related securities. Credit-related losses are recognized as an allowance for credit losses on the balance sheet with a corresponding adjustment to earnings. Unrealized gains and losses that are unrelated to credit deterioration are reported in accumulated other comprehensive income (loss). No credit-related losses or allowance for credit losses were necessary during the periods presented. Fair Value of Financial Instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. The carrying amounts of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other liabilities approximate their respective fair values due to their short-term nature. Leases The Company determines if an arrangement includes a lease at inception by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Operating leases with a term of more than one year are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities on the Company's condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments. Operating lease ROU assets and liabilities are recognized on the lease commencement date based on the present value of the future minimum lease payments over the lease term. The Company uses the incremental borrowing rate commensurate with the lease term based on the information available at the lease commencement date in determining the present value of the lease payments as the Company's leases generally do not provide an implicit rate. ROU assets initially equal the lease liability, adjusted for any prepaid lease payments and initial direct costs incurred, less any lease incentives received. Certain of the Company's leases include renewal options which allow the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These renewal periods are included in the lease terms when the Company is reasonably certain the options will be exercised. Lease expense is recognized on a straight-line basis over the lease term when leases are operating leases. If it is considered a finance lease, expense is recognized over the lease term within interest expense and amortization in the Company’s condensed consolidated statements of operations. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases and to account for the lease and non-lease components as a single lease component. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less. Comprehensive Loss Comprehensive loss consists of net loss and other gains or losses affecting stockholders’ equity that, under U.S. GAAP are excluded from net loss. For the three months ended March 31, 2024 and 2023, net unrealized gains and losses on marketable debt securities were included as a component of comprehensive income (loss). Accounting Pronouncements The Company is provided the option to adopt new or revised accounting guidance as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) either (1) within the same periods as those otherwise applicable to public business entities, or (2) within the same time periods as non-public business entities, including early adoption when permissible. With the exception of standards the Company elected to early adopt, when permissible, the Company has elected to adopt new or revised accounting guidance within the same time period as non-public business entities, as indicated below. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which amends existing guidance on segment reporting to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The ASU is effective for the Company for the fiscal year ending December 31, 2024 and for interim periods beginning after December 31, 2024. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for the Company for the fiscal year ending December 31, 2025. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures. The Company does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table details the assets carried at fair value and measured on a recurring basis within the three levels of fair value as of March 31, 2024 and December 31, 2023: (in thousands) Gross Unrealized Reported as: March 31, 2024 Amortized Cost Gains Losses Fair Value Cash equivalents Short-term investments Long-term investments Level 1 Mutual funds $ 438 $ — $ — $ 438 $ 438 $ — $ — U.S. treasury securities 58,505 8 (172) 58,341 — 41,784 16,557 Total Level 1 58,943 8 (172) 58,779 438 41,784 16,557 Level 2 Commercial paper 25,131 — (13) 25,118 25,118 — — Corporate debt securities 6,969 — (27) 6,942 — 6,942 — Agency securities 157,187 17 (558) 156,646 — 106,911 49,735 Total Level 2 189,287 17 (598) 188,706 25,118 113,853 49,735 Total Level 1 and Level 2 $ 248,230 $ 25 $ (770) $ 247,485 $ 25,556 $ 155,637 $ 66,292 (in thousands) Gross Unrealized Reported as: December 31, 2023 Amortized Cost Gains Losses Fair Value Cash equivalents Short-term investments Long-term investments Level 1 Mutual funds $ 590 $ — $ — $ 590 $ 590 $ — $ — U.S. treasury securities 74,115 104 (247) 73,972 — 50,638 23,334 Total Level 1 74,705 104 (247) 74,562 590 50,638 23,334 Level 2 Commercial paper 18,653 — (9) 18,644 18,644 — — Corporate debt securities 6,950 — (37) 6,913 — 6,913 — Agency securities 163,849 358 (424) 163,783 — 96,470 67,313 Total Level 2 189,452 358 (470) 189,340 18,644 103,383 67,313 Total Level 1 and Level 2 $ 264,157 $ 462 $ (717) $ 263,902 $ 19,234 $ 154,021 $ 90,647 Short-term investments have a contractual maturity date that is one year or less from the respective balance sheet date. Long-term investments have a contractual maturity date that is more than one year, but less than two years from the respective balance sheet date. The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of March 31, 2024 and December 31, 2023 are as follows: (in thousands) Securities in Unrealized Loss Position Less than 12 months Securities in Unrealized Loss Position Greater than 12 months Total March 31, 2024 Gross Unrealized Losses Fair Market Value Gross Unrealized Losses Fair Market Value Gross Unrealized Losses Fair Market Value U.S. treasury securities $ 131 $ 37,090 $ 41 $ 14,436 $ 172 $ 51,526 Commercial paper 13 25,118 — — 13 25,118 Corporate debt securities 27 6,942 — — 27 6,942 Agency securities 450 120,475 108 20,795 558 141,270 Total $ 621 $ 189,625 $ 149 $ 35,231 $ 770 $ 224,856 (in thousands) Securities in Unrealized Loss Position Less than 12 months Securities in Unrealized Loss Position Greater than 12 months Total December 31, 2023 Gross Unrealized Losses Fair Market Value Gross Unrealized Losses Fair Market Value Gross Unrealized Losses Fair Market Value U.S. treasury securities $ 85 $ 20,408 $ 162 $ 30,230 $ 247 $ 50,638 Commercial paper 9 18,644 — — 9 18,644 Corporate debt securities 37 6,913 — — 37 6,913 Agency securities 229 85,039 195 25,704 424 110,743 Total $ 360 $ 131,004 $ 357 $ 55,934 $ 717 $ 186,938 The Company reviewed its investment portfolio based on the underlying risk profile of the securities and have a no loss expectation for these investments. The Company reviewed the securities in an unrealized loss position and evaluated the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The Company recognized no credit losses during the three months ended March 31, 2024 and 2023, and had no allowance for credit losses as of March 31, 2024 and December 31, 2023.

Composition of Certain Condense

Composition of Certain Condensed Consolidated Financial Statement Line Items	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Composition of Certain Condensed Consolidated Financial Statement Line Items	Composition of Certain Condensed Consolidated Financial Statement Line Items Property and Equipment, Net Property and equipment consisted of the following: (in thousands) March 31, December 31, Laboratory equipment $ 6,402 $ 6,337 Leasehold improvements 118 118 Computer hardware 222 222 Furniture, fixtures and office equipment 324 324 Prototype equipment 1,473 996 Construction in progress 1,132 904 9,671 8,901 Less: Accumulated depreciation (5,146) (4,634) Total $ 4,525 $ 4,267 The Company recorded depreciation expense of $0.5 million and $0.4 million for the three months ended March 31, 2024 and 2023, respectively, which was primarily allocated to research and development expense. Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following: (in thousands) March 31, December 31, Employee compensation $ 2,299 $ 2,590 Accrued research and development 760 731 Accrued professional and consulting fees 319 245 Other 299 379 Total $ 3,677 $ 3,945 Cash, Cash Equivalents and Restricted Cash Cash, cash equivalents and restricted cash consisted of the following: (in thousands) March 31, December 31, Cash and cash equivalents $ 25,729 $ 19,397 Restricted cash included in other long-term assets (Note 8) 1,002 1,002 Total $ 26,731 $ 20,399 Other long-term assets consisted of $1.0 million of restricted cash and $0.2 million of deposits as of March 31, 2024, and $1.0 million of restricted cash and $0.2 million of deposits as of December 31, 2023.

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Common Stock	Common Stock There were 125,265,015 shares issued and outstanding as of March 31, 2024. Common Stock Reserved for Future Issuance Shares of common stock reserved for future issuance on an as-if converted basis, were as follows: March 31, December 31, Shares available for grant under 2021 Equity Incentive Plan 24,707,942 20,279,560 Stock options issued and outstanding 16,304,969 14,676,335 Shares available for grant under 2021 Employee Stock Purchase Plan 4,755,824 3,505,138 Total shares of common stock reserved 45,768,735 38,461,033

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. For the three months ended March 31, 2024 and 2023, no income tax expense or benefit was recognized, due to a full valuation allowance recorded against its deferred tax assets.

Equity Incentive Plans and Stoc

Equity Incentive Plans and Stock-based Compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans and Stock-based Compensation	Equity Incentive Plans and Stock-based Compensation On June 8, 2021, the stockholders of the Company approved the 2021 Equity Incentive Plan (“2021 Plan”) and the 2021 Employee Stock Purchase Plan ( “2021 ESPP”). As of March 31, 2024, 24,707,942 and 4,755,824 shares were available for grant under the 2021 Plan and 2021 ESPP, respectively. 2021 Employee Stock Purchase Plan Under the 2021 ESPP, participants are permitted to purchase shares of Common Stock, up to the IRS allowable limit, through contributions (in the form of payroll deductions or otherwise to the extent permitted by the administrator of the 2021 ESPP) of up to 15% of their eligible compensation. Participants are permitted to purchase shares of the Company’s Common Stock at 85% of the lower of the fair market value of the Company’s Common Stock on the first trading day of an offering period or on the last trading date in each purchase period. The Company offers a six month purchase period. Participants may end their participation at any time during an offering and will be paid their accrued contributions that have not yet been used to purchase shares. Participation ends automatically upon termination of employment with the Company. The number of shares of common stock available for issuance under the 2021 ESPP will be increased on the first day of each fiscal year beginning on January 1, 2022, in an amount equal to the least of (i) 3,734,500 shares of common stock, (ii) a number of s hares of common stock equal to one percent (1%) of the total number of shares of all classes of common stock of the Company on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Administrator no later than the last day of the immediately preceding fiscal year. On January 1, 2024, the number of shares available under the 2021 ESPP increased by 1,250,686 shares pursuant to this feature. 2021 Equity Incentive Plan Under the 2021 Plan, the Company can grant incentive stock options, nonstatutory stock options, stock appreciation rig hts, restricted stock, restricted stock units and performance awards to employees, non-employee directors and consultants. Options generally expire ten years after the date of grant. The number of shares available for issuance under the 2021 Plan will be increased on the first day of each fiscal year, beginning on January 1, 2022, in an amount equal to the least of (i) 18,672,200 shares, (ii) a number of shares equal to five percent (5%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Administrator no later than the last day of the immediately preceding fiscal year . On January 1, 2024, the number of shares available under the 2021 Plan increased by 6,253,430 shares pursuant to this feature. 2017 Equity Incentive Plan At the time of adoption of the 2021 Plan and the 2021 ESPP, no further awards will be granted under the 2017 Equity Incentive Plan (“2017 Plan”). Stock-based awards forfeited or cancelled from the 2017 Plan are returned to the pool of shares of Common Stock available for issuance under the 2021 Plan. Grant Date Fair Value of Stock Options In determining the compensation cost of the option awards, the fair value for each option award has been estimated using the Black Scholes model . The significant assumptions used in these calculations are summarized as follows: Three Months Ended March 31, 2024 2023 Expected term (in years) 6.0 6.0 - 6.4 Expected volatility 99.7% - 100.1% 102.7% - 107.5% Expected dividend rate 0.0 % 0.0 % Risk free interest rate 4.01% - 4.22% 3.50% - 4.08% Expected term: The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding. The Company does not have sufficient historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term of options and has opted to use the “simplified method,” whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. Expected volatility: Historically, the Company has been a private company and lacked company‑specific historical and implied volatility information for its common stock. Therefore, the expected volatility of the Company’s common stock was determined by using an average of historical volatilities of selected industry peers deemed to be comparable to the Company’s business corresponding to the expected term of the awards and the Company expects to continue to do so until such time as the Company has adequate historical data regarding the volatility of its traded common stock price. Expected dividend yield: The expected dividend rate is zero as the Company has no history or expectation of declaring dividends on its common stock. Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities corresponding to the expected term of the awards. The following table summarizes option award activity during the three months ended March 31, 2024: Number of Stock Option Awards Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2023 14,676,335 $ 3.63 Granted 2,003,800 $ 2.72 Exercised (196,414) $ 1.24 Forfeited (178,752) $ 3.13 Outstanding as of March 31, 2024 16,304,969 $ 3.55 7.9 $ 11,061 Options vested and expected to vest as of March 31, 2024 16,304,969 $ 3.55 Vested and exercisable at March 31, 2024 8,592,134 $ 3.85 7.1 $ 7,785 As of March 31, 2024, there was $20.0 million of total unrecognized compensation expense expected to be recognized over a weighted average-period of 2.3 years. Aggregate intrinsic value represents the difference between the fair market value of the common stock and the exercise price of outstanding, in-the-money options. Stock-based Compensation Expense The following sets forth the total stock-based compensation expense included in the Company’s condensed consolidated statement of operations: Three Months Ended March 31, (in thousands) 2024 2023 Research and development $ 1,096 $ 975 General and administrative 2,018 1,885 Total stock-based compensation expense $ 3,114 $ 2,860

Commitment and Contingencies

Commitment and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Commitments Open purchase commitments are for the purchase of goods and services related to, but not limited to, research and development, facilities, and professional services under non-cancellable contracts. They were not recorded as liabilities on the condensed consolidated balance sheet as of March 31, 2024 as the Company had not yet received the related goods or services. As of March 31, 2024, the Company had open purchase commitments for goods and services of $2.4 million, of which $1.8 million are expected to be received through the next 12 months. Legal Proceedings From time to time, the Company may become involved in litigation relating to claims arising from the ordinary course of business where the expense, distraction and/or the ultimate disposition could have a material adverse effect on the Company’s results of operations, financial condition or cash flows. The Company filed suit in the United States District Court for the Northern District of California against Somalogic (now known as Standard Biotools, Inc.), and the California Institute of Technology seeking declaratory judgment that the Company does not infringe any claims of US Patent No. 7,842,793 related to DNA origami structures, allegedly licensed from the California Institute of Technology through Somalogic’s purchase of Palamedrix, Inc. On March 29, 2024, Somalogic filed a motion to dismiss the suit. On April 19, 2024, the Company filed a First Amended Complaint addressing issues raised in Somalogic’s motion to dismiss. On April 22, 2024, the Court issued an order dismissing Somalogic’s motion to dismiss as moot. While the Company believes that it will be able to prevail as to its claims in this litigation, the Company may incur significant expense and management distraction in prosecuting this litigation. Moreover, notwithstanding management’s belief as to the strength of the Company’s claims in this matter, litigation generally, and patent litigation in particular, can be unpredictable. As such, management cannot be certain that the Company will prevail in this litigation. Leases The Company is obligated under certain non-cancellable operating leases for office space and laboratory space. This space includes operating leases in Seattle, Washington, San Carlos, California, and San Diego, California. The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of March 31, 2024: Lease Obligations (in thousands) Nine months ending December 31, 2024 4,674 2025 7,182 2026 6,874 2027 6,889 2028 5,816 2029 and thereafter 13,207 Total future minimum lease payments 44,642 Less: Imputed interest (11,021) Total operating lease liabilities $ 33,621 For the three months ended March 31, 2024 and 2023, cash paid for amounts included in the measurement of operating lease liabilities included in cash flows used in operating activities was $1.7 million and $1.2 million, respectively. The Company has $1.0 million in cash-collateralized letters of credit with one financial institution in lieu of security deposits in connection with the San Carlos and San Diego lease agreements. Indemnification Agreements In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnifications will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions.
Commitments and Contingencies	Commitments and Contingencies Purchase Commitments Open purchase commitments are for the purchase of goods and services related to, but not limited to, research and development, facilities, and professional services under non-cancellable contracts. They were not recorded as liabilities on the condensed consolidated balance sheet as of March 31, 2024 as the Company had not yet received the related goods or services. As of March 31, 2024, the Company had open purchase commitments for goods and services of $2.4 million, of which $1.8 million are expected to be received through the next 12 months. Legal Proceedings From time to time, the Company may become involved in litigation relating to claims arising from the ordinary course of business where the expense, distraction and/or the ultimate disposition could have a material adverse effect on the Company’s results of operations, financial condition or cash flows. The Company filed suit in the United States District Court for the Northern District of California against Somalogic (now known as Standard Biotools, Inc.), and the California Institute of Technology seeking declaratory judgment that the Company does not infringe any claims of US Patent No. 7,842,793 related to DNA origami structures, allegedly licensed from the California Institute of Technology through Somalogic’s purchase of Palamedrix, Inc. On March 29, 2024, Somalogic filed a motion to dismiss the suit. On April 19, 2024, the Company filed a First Amended Complaint addressing issues raised in Somalogic’s motion to dismiss. On April 22, 2024, the Court issued an order dismissing Somalogic’s motion to dismiss as moot. While the Company believes that it will be able to prevail as to its claims in this litigation, the Company may incur significant expense and management distraction in prosecuting this litigation. Moreover, notwithstanding management’s belief as to the strength of the Company’s claims in this matter, litigation generally, and patent litigation in particular, can be unpredictable. As such, management cannot be certain that the Company will prevail in this litigation. Leases The Company is obligated under certain non-cancellable operating leases for office space and laboratory space. This space includes operating leases in Seattle, Washington, San Carlos, California, and San Diego, California. The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of March 31, 2024: Lease Obligations (in thousands) Nine months ending December 31, 2024 4,674 2025 7,182 2026 6,874 2027 6,889 2028 5,816 2029 and thereafter 13,207 Total future minimum lease payments 44,642 Less: Imputed interest (11,021) Total operating lease liabilities $ 33,621 For the three months ended March 31, 2024 and 2023, cash paid for amounts included in the measurement of operating lease liabilities included in cash flows used in operating activities was $1.7 million and $1.2 million, respectively. The Company has $1.0 million in cash-collateralized letters of credit with one financial institution in lieu of security deposits in connection with the San Carlos and San Diego lease agreements. Indemnification Agreements In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnifications will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions.

Basic and Diluted Net Loss per

Basic and Diluted Net Loss per Share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share The following tables set forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three months ended March 31, 2024 and 2023: Three Months Ended March 31, (in thousands, except share and per share amounts) 2024 2023 Numerator: Net loss attributable to common stockholders $ (18,730) $ (14,965) Denominator: Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted 125,135,451 124,590,351 Net loss per share attributable to common stockholders, basic and diluted: $ (0.15) $ (0.12) The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows: Three Months Ended March 31, 2024 2023 Options to purchase common stock 16,304,969 13,603,285 Employee stock purchase plan 133,978 60,694 Total potentially dilutive common share equivalents 16,438,947 13,663,979

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net loss	$ (18,730)	$ (14,965)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for interim financial reporting. All intercompany transactions and balances have been eliminated upon consolidation. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements were prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods. The interim financial results are not necessarily indicative of the results for a full year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 on file with the SEC. The Company’s reporting currency is the U.S. dollar.
Use of Estimates	The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determining the estimated lives of property and equipment, stock-based compensation, research and development accruals, and the valuation allowance for deferred tax assets. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods. As future events and their effects cannot be determined with precision, actual results could materially differ from those estimates and assumptions.
Concentrations of Credit Risk and Other Risks and Uncertainties	Credit risk represents the accounting loss that would be recognized as of the reporting date if counterparties failed to perform as contracted. Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash balances maintained in excess of federal depository insurance limits and investments in marketable debt securities that are not federally insured. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk on cash or investments. The Company relies, and expects to continue to rely, on a number of vendors to provide services, supplies and materials related to its research and development programs. The Company relies on single source suppliers for certain components and materials used in the Nautilus platform. The loss of any of these single source suppliers would require the Company to expend significant time and effort to locate and qualify an alternative source of supply for these components. The Company also relies, and expects to continue to rely, on third-party manufacturers and, in many cases, single third-party manufacturers for the production of certain reagents and antibodies. These programs could be adversely affected by a significant interruption in these services or the availability of materials. The Company is subject to risks similar to those of pre-clinical stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of negative global and national events and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.
Segment Reporting	Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision m aker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s Chief Executive Officer is its CODM. The Company’s CODM re
Cash and Cash Equivalents	The Company considers all highly-liquid investments with an original maturity of three months or less as of the date of acquisition to be cash equivalents.
Investments	The Company considers investments with an original maturity greater than three months and remaining maturities less than one year to be short-term investments. The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as long-term investments. The Company classifies its marketable debt securities as available for sale and reports them at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For investments sold prior to maturity, the cost of investments sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in other income (expense), net in the condensed consolidated statement of operations. If the estimated fair value of a marketable debt security is below its amortized cost basis, the Company evaluates whether it is more likely than not that the Company will be required to sell the security before its anticipated recovery in market value and whether credit losses exist for the related securities. Credit-related losses are recognized as an allowance for credit losses on the balance sheet with a corresponding adjustment to earnings. Unrealized gains and losses that are unrelated to credit deterioration are reported in accumulated other comprehensive income (loss). No credit-related losses or allowance for credit losses were necessary during the periods presented.
Fair Value of Financial Instruments	Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. The carrying amounts of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other liabilities approximate their respective fair values due to their short-term nature.
Leases	The Company determines if an arrangement includes a lease at inception by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Operating leases with a term of more than one year are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities on the Company's condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments. Operating lease ROU assets and liabilities are recognized on the lease commencement date based on the present value of the future minimum lease payments over the lease term. The Company uses the incremental borrowing rate commensurate with the lease term based on the information available at the lease commencement date in determining the present value of the lease payments as the Company's leases generally do not provide an implicit rate. ROU assets initially equal the lease liability, adjusted for any prepaid lease payments and initial direct costs incurred, less any lease incentives received. Certain of the Company's leases include renewal options which allow the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These renewal periods are included in the lease terms when the Company is reasonably certain the options will be exercised. Lease expense is recognized on a straight-line basis over the lease term when leases are operating leases. If it is considered a finance lease, expense is recognized over the lease term within interest expense and amortization in the Company’s condensed consolidated statements of operations. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases and to account for the lease and non-lease components as a single lease component. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.
Comprehensive Loss	Comprehensive loss consists of net loss and other gains or losses affecting stockholders’ equity that, under U.S. GAAP are excluded from net loss. For the three months ended March 31, 2024 and 2023, net unrealized gains and losses on marketable debt securities were included as a component of comprehensive income (loss).
Accounting Pronouncements	The Company is provided the option to adopt new or revised accounting guidance as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) either (1) within the same periods as those otherwise applicable to public business entities, or (2) within the same time periods as non-public business entities, including early adoption when permissible. With the exception of standards the Company elected to early adopt, when permissible, the Company has elected to adopt new or revised accounting guidance within the same time period as non-public business entities, as indicated below. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which amends existing guidance on segment reporting to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The ASU is effective for the Company for the fiscal year ending December 31, 2024 and for interim periods beginning after December 31, 2024. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for the Company for the fiscal year ending December 31, 2025. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures. The Company does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Assets Carried at Fair Value and Measured on a Recurring Basis	The following table details the assets carried at fair value and measured on a recurring basis within the three levels of fair value as of March 31, 2024 and December 31, 2023: (in thousands) Gross Unrealized Reported as: March 31, 2024 Amortized Cost Gains Losses Fair Value Cash equivalents Short-term investments Long-term investments Level 1 Mutual funds $ 438 $ — $ — $ 438 $ 438 $ — $ — U.S. treasury securities 58,505 8 (172) 58,341 — 41,784 16,557 Total Level 1 58,943 8 (172) 58,779 438 41,784 16,557 Level 2 Commercial paper 25,131 — (13) 25,118 25,118 — — Corporate debt securities 6,969 — (27) 6,942 — 6,942 — Agency securities 157,187 17 (558) 156,646 — 106,911 49,735 Total Level 2 189,287 17 (598) 188,706 25,118 113,853 49,735 Total Level 1 and Level 2 $ 248,230 $ 25 $ (770) $ 247,485 $ 25,556 $ 155,637 $ 66,292 (in thousands) Gross Unrealized Reported as: December 31, 2023 Amortized Cost Gains Losses Fair Value Cash equivalents Short-term investments Long-term investments Level 1 Mutual funds $ 590 $ — $ — $ 590 $ 590 $ — $ — U.S. treasury securities 74,115 104 (247) 73,972 — 50,638 23,334 Total Level 1 74,705 104 (247) 74,562 590 50,638 23,334 Level 2 Commercial paper 18,653 — (9) 18,644 18,644 — — Corporate debt securities 6,950 — (37) 6,913 — 6,913 — Agency securities 163,849 358 (424) 163,783 — 96,470 67,313 Total Level 2 189,452 358 (470) 189,340 18,644 103,383 67,313 Total Level 1 and Level 2 $ 264,157 $ 462 $ (717) $ 263,902 $ 19,234 $ 154,021 $ 90,647
Schedule of Unrealized Losses and Fair Values of Available-for-Sale Securities in an Unrealized Loss Position	The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of March 31, 2024 and December 31, 2023 are as follows: (in thousands) Securities in Unrealized Loss Position Less than 12 months Securities in Unrealized Loss Position Greater than 12 months Total March 31, 2024 Gross Unrealized Losses Fair Market Value Gross Unrealized Losses Fair Market Value Gross Unrealized Losses Fair Market Value U.S. treasury securities $ 131 $ 37,090 $ 41 $ 14,436 $ 172 $ 51,526 Commercial paper 13 25,118 — — 13 25,118 Corporate debt securities 27 6,942 — — 27 6,942 Agency securities 450 120,475 108 20,795 558 141,270 Total $ 621 $ 189,625 $ 149 $ 35,231 $ 770 $ 224,856 (in thousands) Securities in Unrealized Loss Position Less than 12 months Securities in Unrealized Loss Position Greater than 12 months Total December 31, 2023 Gross Unrealized Losses Fair Market Value Gross Unrealized Losses Fair Market Value Gross Unrealized Losses Fair Market Value U.S. treasury securities $ 85 $ 20,408 $ 162 $ 30,230 $ 247 $ 50,638 Commercial paper 9 18,644 — — 9 18,644 Corporate debt securities 37 6,913 — — 37 6,913 Agency securities 229 85,039 195 25,704 424 110,743 Total $ 360 $ 131,004 $ 357 $ 55,934 $ 717 $ 186,938

Composition of Certain Conden_2

Composition of Certain Condensed Consolidated Financial Statement Line Items (Tables)	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Property and Equipment, Net	Property and equipment consisted of the following: (in thousands) March 31, December 31, Laboratory equipment $ 6,402 $ 6,337 Leasehold improvements 118 118 Computer hardware 222 222 Furniture, fixtures and office equipment 324 324 Prototype equipment 1,473 996 Construction in progress 1,132 904 9,671 8,901 Less: Accumulated depreciation (5,146) (4,634) Total $ 4,525 $ 4,267
Schedule of Accrued Expenses	Accrued expenses and other liabilities consisted of the following: (in thousands) March 31, December 31, Employee compensation $ 2,299 $ 2,590 Accrued research and development 760 731 Accrued professional and consulting fees 319 245 Other 299 379 Total $ 3,677 $ 3,945
Schedule of Other Liabilities	Accrued expenses and other liabilities consisted of the following: (in thousands) March 31, December 31, Employee compensation $ 2,299 $ 2,590 Accrued research and development 760 731 Accrued professional and consulting fees 319 245 Other 299 379 Total $ 3,677 $ 3,945
Schedule of Cash and Cash Equivalents	Cash, cash equivalents and restricted cash consisted of the following: (in thousands) March 31, December 31, Cash and cash equivalents $ 25,729 $ 19,397 Restricted cash included in other long-term assets (Note 8) 1,002 1,002 Total $ 26,731 $ 20,399
Schedule of Restricted Cash	Cash, cash equivalents and restricted cash consisted of the following: (in thousands) March 31, December 31, Cash and cash equivalents $ 25,729 $ 19,397 Restricted cash included in other long-term assets (Note 8) 1,002 1,002 Total $ 26,731 $ 20,399

Common Stock (Tables)

Common Stock (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of Common Stock Reserved for Future Issuance	Shares of common stock reserved for future issuance on an as-if converted basis, were as follows: March 31, December 31, Shares available for grant under 2021 Equity Incentive Plan 24,707,942 20,279,560 Stock options issued and outstanding 16,304,969 14,676,335 Shares available for grant under 2021 Employee Stock Purchase Plan 4,755,824 3,505,138 Total shares of common stock reserved 45,768,735 38,461,033

Equity Incentive Plans and St_2

Equity Incentive Plans and Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Significant Assumptions	The significant assumptions used in these calculations are summarized as follows: Three Months Ended March 31, 2024 2023 Expected term (in years) 6.0 6.0 - 6.4 Expected volatility 99.7% - 100.1% 102.7% - 107.5% Expected dividend rate 0.0 % 0.0 % Risk free interest rate 4.01% - 4.22% 3.50% - 4.08%
Schedule of Option Award Activity	The following table summarizes option award activity during the three months ended March 31, 2024: Number of Stock Option Awards Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2023 14,676,335 $ 3.63 Granted 2,003,800 $ 2.72 Exercised (196,414) $ 1.24 Forfeited (178,752) $ 3.13 Outstanding as of March 31, 2024 16,304,969 $ 3.55 7.9 $ 11,061 Options vested and expected to vest as of March 31, 2024 16,304,969 $ 3.55 Vested and exercisable at March 31, 2024 8,592,134 $ 3.85 7.1 $ 7,785
Schedule of Stock-Based Compensation Expense	The following sets forth the total stock-based compensation expense included in the Company’s condensed consolidated statement of operations: Three Months Ended March 31, (in thousands) 2024 2023 Research and development $ 1,096 $ 975 General and administrative 2,018 1,885 Total stock-based compensation expense $ 3,114 $ 2,860

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Summary of Future Principal Contractual Obligations for Operating Lease Commitments	The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of March 31, 2024: Lease Obligations (in thousands) Nine months ending December 31, 2024 4,674 2025 7,182 2026 6,874 2027 6,889 2028 5,816 2029 and thereafter 13,207 Total future minimum lease payments 44,642 Less: Imputed interest (11,021) Total operating lease liabilities $ 33,621

Basic and Diluted Net Loss pe_2

Basic and Diluted Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following tables set forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three months ended March 31, 2024 and 2023: Three Months Ended March 31, (in thousands, except share and per share amounts) 2024 2023 Numerator: Net loss attributable to common stockholders $ (18,730) $ (14,965) Denominator: Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted 125,135,451 124,590,351 Net loss per share attributable to common stockholders, basic and diluted: $ (0.15) $ (0.12)
Schedule of Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share	The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows: Three Months Ended March 31, 2024 2023 Options to purchase common stock 16,304,969 13,603,285 Employee stock purchase plan 133,978 60,694 Total potentially dilutive common share equivalents 16,438,947 13,663,979

Description of Business and B_2

Description of Business and Basis of Presentation (Details) - USD ($)		1 Months Ended
	Jun. 09, 2021	Jun. 30, 2021	Mar. 31, 2024	Dec. 31, 2023
Subsidiary, Sale of Stock [Line Items]
Accumulated deficit			$ 220,969,000	$ 202,239,000
Proceeds from sale of stock and reverse recapitalization transaction		$ 345,500,000
Payments of transaction costs		$ 18,200,000
Cash, cash equivalents, and short-term investments			$ 181,400,000
Private Placement
Subsidiary, Sale of Stock [Line Items]
Shares issued in transaction (in shares)	20,000,000
Price per share (in dollars per share)	$ 10
Consideration received on transaction	$ 200,000,000

Significant Accounting Polici_3

Significant Accounting Policies (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) segment	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
Number of operating segments | segment	1
Number of reportable segments | segment	1
Credit losses during period | $	$ 0	$ 0
Allowance for credit losses | $	$ 0	$ 0

Fair Value Measurements - Asset

Fair Value Measurements - Assets Carried at Fair Value and Measured on a Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 248,230	$ 264,157
Gains	25	462
Losses	(770)	(717)
Fair Value	247,485	263,902
Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	25,556	19,234
Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	155,637	154,021
Long-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	66,292	90,647
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	58,943	74,705
Gains	8	104
Losses	(172)	(247)
Fair Value	58,779	74,562
Level 1 | Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	438	590
Level 1 | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	41,784	50,638
Level 1 | Long-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	16,557	23,334
Level 1 | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	438	590
Gains	0	0
Losses	0	0
Fair Value	438	590
Level 1 | Mutual funds | Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	438	590
Level 1 | Mutual funds | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0	0
Level 1 | Mutual funds | Long-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0	0
Level 1 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	58,505	74,115
Gains	8	104
Losses	(172)	(247)
Fair Value	58,341	73,972
Level 1 | U.S. treasury securities | Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0	0
Level 1 | U.S. treasury securities | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	41,784	50,638
Level 1 | U.S. treasury securities | Long-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	16,557	23,334
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	189,287	189,452
Gains	17	358
Losses	(598)	(470)
Fair Value	188,706	189,340
Level 2 | Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	25,118	18,644
Level 2 | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	113,853	103,383
Level 2 | Long-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	49,735	67,313
Level 2 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	25,131	18,653
Gains	0	0
Losses	(13)	(9)
Fair Value	25,118	18,644
Level 2 | Commercial paper | Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	25,118	18,644
Level 2 | Commercial paper | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0	0
Level 2 | Commercial paper | Long-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0	0
Level 2 | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	6,969	6,950
Gains	0	0
Losses	(27)	(37)
Fair Value	6,942	6,913
Level 2 | Corporate debt securities | Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0	0
Level 2 | Corporate debt securities | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	6,942	6,913
Level 2 | Corporate debt securities | Long-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0	0
Level 2 | Agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	157,187	163,849
Gains	17	358
Losses	(558)	(424)
Fair Value	156,646	163,783
Level 2 | Agency securities | Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0	0
Level 2 | Agency securities | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	106,911	96,470
Level 2 | Agency securities | Long-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 49,735	$ 67,313

Fair Value Measurements - Unrea

Fair Value Measurements - Unrealized Losses and Fair Values of Available-for-Sale Securities in an Unrealized Loss Position (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Gross Unrealized Losses
Securities in Unrealized Loss Position Less than 12 months	$ 621	$ 360
Securities in Unrealized Loss Position Greater than 12 months	149	357
Total	770	717
Fair Market Value
Securities in Unrealized Loss Position Less than 12 months	189,625	131,004
Securities in Unrealized Loss Position Greater than 12 months	35,231	55,934
Total	224,856	186,938
U.S. treasury securities
Gross Unrealized Losses
Securities in Unrealized Loss Position Less than 12 months	131	85
Securities in Unrealized Loss Position Greater than 12 months	41	162
Total	172	247
Fair Market Value
Securities in Unrealized Loss Position Less than 12 months	37,090	20,408
Securities in Unrealized Loss Position Greater than 12 months	14,436	30,230
Total	51,526	50,638
Commercial paper
Gross Unrealized Losses
Securities in Unrealized Loss Position Less than 12 months	13	9
Securities in Unrealized Loss Position Greater than 12 months	0	0
Total	13	9
Fair Market Value
Securities in Unrealized Loss Position Less than 12 months	25,118	18,644
Securities in Unrealized Loss Position Greater than 12 months	0	0
Total	25,118	18,644
Corporate debt securities
Gross Unrealized Losses
Securities in Unrealized Loss Position Less than 12 months	27	37
Securities in Unrealized Loss Position Greater than 12 months	0	0
Total	27	37
Fair Market Value
Securities in Unrealized Loss Position Less than 12 months	6,942	6,913
Securities in Unrealized Loss Position Greater than 12 months	0	0
Total	6,942	6,913
Agency securities
Gross Unrealized Losses
Securities in Unrealized Loss Position Less than 12 months	450	229
Securities in Unrealized Loss Position Greater than 12 months	108	195
Total	558	424
Fair Market Value
Securities in Unrealized Loss Position Less than 12 months	120,475	85,039
Securities in Unrealized Loss Position Greater than 12 months	20,795	25,704
Total	$ 141,270	$ 110,743

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Credit losses during period	$ 0	$ 0
Allowance for credit losses	$ 0	$ 0

Composition of Certain Conden_3

Composition of Certain Condensed Consolidated Financial Statement Line Items - Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 9,671		$ 8,901
Less: Accumulated depreciation	(5,146)		(4,634)
Total	4,525		4,267
Depreciation	516	$ 385
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	6,402		6,337
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	118		118
Computer hardware
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	222		222
Furniture, fixtures and office equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	324		324
Prototype equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,473		996
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,132		$ 904

Composition of Certain Conden_4

Composition of Certain Condensed Consolidated Financial Statement Line Items - Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Employee compensation	$ 2,299	$ 2,590
Accrued research and development	760	731
Accrued professional and consulting fees	319	245
Other	299	379
Total	$ 3,677	$ 3,945

Composition of Certain Conden_5

Composition of Certain Condensed Consolidated Financial Statement Line Items - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 25,729	$ 19,397
Restricted cash included in other long-term assets	1,002	1,002
Total	$ 26,731	$ 20,399	$ 89,459	$ 115,477

Composition of Certain Conden_6

Composition of Certain Condensed Consolidated Financial Statement Line Items - Other Long-term Assets (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Restricted cash	$ 1	$ 1
Deposits	$ 0.2	$ 0.2

Common Stock - Narrative (Detai

Common Stock - Narrative (Details) - shares	Mar. 31, 2024	Dec. 31, 2023
Equity [Abstract]
Common stock, shares issued (in shares)	125,265,015	125,068,601
Common stock, shares outstanding (in shares)	125,265,015	125,068,601

Common Stock - Common Stock Res

Common Stock - Common Stock Reserved for Future Issuance (Details) - shares	Mar. 31, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Stock options issued and outstanding (in shares)	16,304,969	14,676,335
Total shares of common stock reserved (in shares)	45,768,735	38,461,033
2021 Equity Incentive Plan
Class of Stock [Line Items]
Shares available for grant under equity plan (in shares)	24,707,942	20,279,560
2021 Employee Stock Purchase Plan
Class of Stock [Line Items]
Shares available for grant under equity plan (in shares)	4,755,824	3,505,138

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0

Equity Incentive Plans and St_3

Equity Incentive Plans and Stock-based Compensation - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Jan. 01, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 20
Unrecognized compensation expense, period for recognition	2 years 3 months 18 days
2021 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant under equity plan (in shares)	24,707,942			20,279,560
Number of additional shares authorized (in shares)	18,672,200
Percentage of outstanding stock maximum	5%
Increase in shares available for grant under equity plan (in shares)			6,253,430
Award expiration period	10 years
2021 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant under equity plan (in shares)	4,755,824			3,505,138
Offering purchase period	6 months
Number of additional shares authorized (in shares)	3,734,500
Percentage of outstanding stock maximum	1%
Increase in shares available for grant under equity plan (in shares)			1,250,686
Employee Stock | 2021 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase shares of common stock contribution percent	15%
Purchase price of common stock, percent	85%
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend rate	0%	0%

Equity Incentive Plans and St_4

Equity Incentive Plans and Stock-based Compensation - Significant Assumptions (Details) - Options	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	99.70%	102.70%
Expected volatility, maximum	100.10%	107.50%
Expected dividend rate	0%	0%
Risk free interest rate, minimum	4.01%	3.50%
Risk free interest rate, maximum	4.22%	4.08%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years	6 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)		6 years 4 months 24 days

Equity Incentive Plans and St_5

Equity Incentive Plans and Stock-based Compensation - Option Award Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Number of Stock Option Awards
Outstanding beginning balance (in shares) | shares	14,676,335
Granted (in shares) | shares	2,003,800
Exercised (in shares) | shares	(196,414)
Forfeited (in shares) | shares	(178,752)
Outstanding ending balance (in shares) | shares	16,304,969
Options vested and expected to vest (in shares) | shares	16,304,969
Vested and exercisable (in shares) | shares	8,592,134
Weighted Average Exercise Price
Outstanding beginning balance (in dollars per share) | $ / shares	$ 3.63
Granted (in dollars per share) | $ / shares	2.72
Exercised (in dollars per share) | $ / shares	1.24
Forfeited (in dollars per share) | $ / shares	3.13
Outstanding ending balance (in dollars per share) | $ / shares	3.55
Options vested and expected to vest (in dollars per share) | $ / shares	3.55
Vested and exercisable (in dollars per share) | $ / shares	$ 3.85
Options outstanding, weighted average remaining contractual life	7 years 10 months 24 days
Vested and exercisable, weighted average remaining contractual life	7 years 1 month 6 days
Options outstanding, aggregate intrinsic value | $	$ 11,061
Vested and exercisable, aggregate intrinsic value | $	$ 7,785

Equity Incentive Plans and St_6

Equity Incentive Plans and Stock-based Compensation - Stock-Based Compensation Expense (Details) - Options - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 3,114	$ 2,860
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,096	975
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,018	$ 1,885

Commitment and Contingencies -

Commitment and Contingencies - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Open purchase commitment	$ 2.4
Purchase commitment, next 12 months	1.8
Cash paid for lease liabilities included in operating activities	1.7	$ 1.2
Letters of credit	$ 1

Commitment and Contingencies _2

Commitment and Contingencies - Future Principal Contractual Obligations for Operating Lease Commitments (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Nine months ending December 31, 2024	$ 4,674
2025	7,182
2026	6,874
2027	6,889
2028	5,816
2029 and thereafter	13,207
Total future minimum lease payments	44,642
Less: Imputed interest	(11,021)
Total operating lease liabilities	$ 33,621

Basic and Diluted Net Loss pe_3

Basic and Diluted Net Loss per Share - Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Net loss attributable to common stockholders, basic	$ (18,730)	$ (14,965)
Net loss attributable to common stockholders, diluted	$ (18,730)	$ (14,965)
Weighted average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	125,135,451	124,590,351
Weighted average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	125,135,451	124,590,351
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.15)	$ (0.12)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.15)	$ (0.12)

Basic and Diluted Net Loss pe_4

Basic and Diluted Net Loss per Share - Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive common share equivalents	16,438,947	13,663,979
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive common share equivalents	16,304,969	13,603,285
Employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive common share equivalents	133,978	60,694